[{"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-001", "question": "A 14-month-old boy with genetically confirmed PMM2-CDG (p.Arg141His and p.Phe119Leu compound heterozygous variants) is scheduled for inguinal hernia repair. Preoperative coagulation studies show antithrombin III 45% (normal 80-120%), protein C 38% (normal 70-140%), and protein S 32% (normal 65-140%). All other labs are normal. What is the most appropriate perioperative management to minimize thrombotic risk?", "options": ["Proceed with surgery without prophylaxis; risk is theoretical", "Administer prophylactic enoxaparin 0.5 mg/kg subcutaneously 12 hours preoperatively and postoperatively", "Transfuse fresh frozen plasma to correct factor deficiencies before surgery", "Delay surgery indefinitely until coagulation factors normalize with nutritional support", "Administer antithrombin III concentrate 50 IU/kg immediately preoperatively"], "answer": "B", "answer_index": 1, "explanation": "PMM2-CDG causes combined antithrombin III, protein C, and protein S deficiency, creating significant thrombotic risk. For surgical prophylaxis, LMWH is recommended to address all deficient pathways. FFP provides insufficient correction and risks volume overload. ATIII concentrate alone doesn't address protein C/S deficiency. The thrombosis risk is not theoretical, with rates of 10-15% in moderate-severe cases.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a 14-month-old with PMM2-CDG and combined deficiencies of natural anticoagulants (antithrombin III, protein C, protein S) undergoing inguinal hernia repair. Key discriminating findings: severe deficiencies of all three natural anticoagulants (all <50% normal), young age (14 months), elective minor surgery. The question asks for perioperative thromboprophylaxis. Option B (prophylactic enoxaparin) and Option E (antithrombin III concentrate) are both defensible. While the rationale dismisses ATIII concentrate as addressing only one pathway, in PMM2-CDG the primary driver of thrombosis is often antithrombin deficiency, and ATIII concentrate is specifically indicated for surgery in severe deficiency (<50%). LMWH dosing in a 14-month-old infant for this indication lacks strong evidence and carries bleeding risk. The stem does not specify disease severity, prior thrombotic events, or institutional protocols that would definitively favor one approach. Both options address thrombotic risk through different mechanisms. Main logical issue: insufficient clinical context to discriminate between two reasonable prophylactic strategies. Main medical accuracy issue: the rationale oversimplifies the role of ATIII concentrate in CDG perioperative management. Minimal fix: specify prior thrombotic history or disease severity to justify LMWH over targeted factor replacement.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a 14-month-old with PMM2-CDG and combined deficiencies of natural anticoagulants (antithrombin III, protein C, protein S) undergoing inguinal hernia repair. Key discriminating findings: severe deficiencies of all three natural anticoagulants (all <50% normal), young age (14 months), elective minor surgery. The question asks for perioperative thromboprophylaxis. Option B (prophylactic enoxaparin) and Option E (antithrombin III concentrate) are both defensible. While the rationale dismisses ATIII concentrate as addressing only one pathway, in PMM2-CDG the primary driver of thrombosis is often antithrombin deficiency, and ATIII concentrate is specifically indicated for surgery in severe deficiency (<50%). LMWH dosing in a 14-month-old infant for this indication lacks strong evidence and carries bleeding risk. The stem does not specify disease severity, prior thrombotic events, or institutional protocols that would definitively favor one approach. Both options address thrombotic risk through different mechanisms. Main logical issue: insufficient clinical context to discriminate between two reasonable prophylactic strategies. Main medical accuracy issue: the rationale oversimplifies the role of ATIII concentrate in CDG perioperative management. Minimal fix: specify prior thrombotic history or disease severity to justify LMWH over targeted factor replacement.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-002", "question": "A 3-year-old girl presents with opsoclonus-myoclonus syndrome and is found to have a right adrenal neuroblastoma with favorable histology, MYCN non-amplified. After tumor resection, neurologic symptoms persist despite high-dose steroids. Which immunotherapy targeting the specific B-cell mediated pathogenesis is most appropriate?", "options": ["Rituximab 375 mg/m² weekly for 4 weeks", "Cyclophosphamide 600 mg/m² monthly for 6 months", "Intravenous immunoglobulin 2 g/kg monthly", "Alemtuzumab 30 mg daily for 5 days", "Tocilizumab 8 mg/kg every 2 weeks"], "answer": "A", "answer_index": 0, "explanation": "Opsoclonus-myoclonus syndrome is mediated by anti-neuronal antibodies produced by B-cells. Rituximab depletes B-cells and is first-line for steroid-refractory cases. IVIG is adjunctive but not primary therapy. Cyclophosphamide is less specific and more toxic. Alemtuzumab is not standard and causes profound lymphodepletion. Tocilizumab targets IL-6, not the primary antibody-mediated pathogenesis.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a 3-year-old with paraneoplastic opsoclonus-myoclonus syndrome (OMS) secondary to neuroblastoma, with steroid-refractory neurologic symptoms post-resection. Key discriminating findings: (1) OMS persisting despite high-dose steroids, (2) favorable-histology neuroblastoma (low oncologic risk), (3) question specifically asks for immunotherapy targeting B-cell mediated pathogenesis. OMS is indeed mediated by anti-neuronal antibodies from B-cells. Rituximab (anti-CD20) directly depletes B-cells and is established second-line therapy for steroid-refractory OMS in current literature. Option A is defensible as best answer. Alternative assessment: (B) Cyclophosphamide is used but less specific, more toxic, and not primarily \\\"B-cell targeting immunotherapy\\\"; (C) IVIG modulates antibodies but doesn't deplete B-cells producing them—adjunctive role; (D) Alemtuzumab targets T-cells (anti-CD52), causes profound pan-lymphodepletion, not standard for OMS; (E) Tocilizumab blocks IL-6 receptor, not directly B-cell targeting. The stem's phrase \\\"immunotherapy targeting the specific B-cell mediated pathogenesis\\\" strongly favors rituximab over alternatives. Medical accuracy: Rituximab use in pediatric OMS is supported by case series and expert consensus, though high-quality RCT data are limited. No major inaccuracies. Minimal fix: None required; item is logically valid and medically sound.\", \"medical_accuracy_score\": \"4\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a 3-year-old with paraneoplastic opsoclonus-myoclonus syndrome (OMS) secondary to neuroblastoma, with steroid-refractory neurologic symptoms post-resection. Key discriminating findings: (1) OMS persisting despite high-dose steroids, (2) favorable-histology neuroblastoma (low oncologic risk), (3) question specifically asks for immunotherapy targeting B-cell mediated pathogenesis. OMS is indeed mediated by anti-neuronal antibodies from B-cells. Rituximab (anti-CD20) directly depletes B-cells and is established second-line therapy for steroid-refractory OMS in current literature. Option A is defensible as best answer. Alternative assessment: (B) Cyclophosphamide is used but less specific, more toxic, and not primarily \"B-cell targeting immunotherapy\"; (C) IVIG modulates antibodies but doesn't deplete B-cells producing them—adjunctive role; (D) Alemtuzumab targets T-cells (anti-CD52), causes profound pan-lymphodepletion, not standard for OMS; (E) Tocilizumab blocks IL-6 receptor, not directly B-cell targeting. The stem's phrase \"immunotherapy targeting the specific B-cell mediated pathogenesis\" strongly favors rituximab over alternatives. Medical accuracy: Rituximab use in pediatric OMS is supported by case series and expert consensus, though high-quality RCT data are limited. No major inaccuracies. Minimal fix: None required; item is logically valid and medically sound.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-003", "question": "A 7-year-old girl with McCune-Albright syndrome (confirmed GNAS R201C mutation) presents with premature thelarche, vaginal bleeding, and a growth velocity of 12 cm/year. Bone age is 10 years. Which endocrine intervention specifically targets the underlying pathophysiology of precocious puberty in this condition?", "options": ["GnRH agonist (leuprolide) 7.5 mg IM monthly", "Aromatase inhibitor (letrozole) 2.5 mg daily", "Estrogen receptor antagonist (tamoxifen) 10 mg twice daily", "Progesterone-only contraceptive (medroxyprogesterone) 10 mg daily", "Ketoconazole 200 mg twice daily"], "answer": "B", "answer_index": 1, "explanation": "In McCune-Albright syndrome, precocious puberty results from autonomous ovarian hyperfunction, not central activation. GnRH agonists are ineffective because the process is gonadotropin-independent. Aromatase inhibitors block peripheral estrogen synthesis from autonomous follicular cysts. Tamoxifen is less effective and has more side effects. Progesterone doesn't address estrogen excess. Ketoconazole has significant toxicity.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a 7-year-old with McCune-Albright syndrome (MAS) presenting with peripheral precocious puberty (premature thelarche, vaginal bleeding, accelerated growth). Key discriminating findings: confirmed GNAS mutation causing constitutive activation of Gs-alpha protein, leading to gonadotropin-independent ovarian function. The question asks which intervention targets the underlying pathophysiology. Option B (aromatase inhibitor) is the best answer because MAS causes autonomous ovarian estrogen production independent of GnRH/gonadotropins; blocking aromatase directly reduces estrogen synthesis from autonomous follicular cysts. Option A (GnRH agonist) is ineffective in peripheral precocious puberty as the HPG axis is not activated. Option C (tamoxifen) blocks estrogen receptors but doesn't address ongoing synthesis and has more side effects in children. Option D (progesterone) doesn't reduce estrogen excess. Option E (ketoconazole) has significant hepatotoxicity and is not first-line. The item is medically accurate: aromatase inhibitors (letrozole, anastrozole) are established treatment for MAS-related precocious puberty per current literature. No logical flaws exist; the stem provides sufficient detail to identify peripheral precocious puberty requiring estrogen synthesis blockade. Minimal fix: None needed; item is valid and accurate.\", \"medical_accuracy_score\": \"4\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a 7-year-old with McCune-Albright syndrome (MAS) presenting with peripheral precocious puberty (premature thelarche, vaginal bleeding, accelerated growth). Key discriminating findings: confirmed GNAS mutation causing constitutive activation of Gs-alpha protein, leading to gonadotropin-independent ovarian function. The question asks which intervention targets the underlying pathophysiology. Option B (aromatase inhibitor) is the best answer because MAS causes autonomous ovarian estrogen production independent of GnRH/gonadotropins; blocking aromatase directly reduces estrogen synthesis from autonomous follicular cysts. Option A (GnRH agonist) is ineffective in peripheral precocious puberty as the HPG axis is not activated. Option C (tamoxifen) blocks estrogen receptors but doesn't address ongoing synthesis and has more side effects in children. Option D (progesterone) doesn't reduce estrogen excess. Option E (ketoconazole) has significant hepatotoxicity and is not first-line. The item is medically accurate: aromatase inhibitors (letrozole, anastrozole) are established treatment for MAS-related precocious puberty per current literature. No logical flaws exist; the stem provides sufficient detail to identify peripheral precocious puberty requiring estrogen synthesis blockade. Minimal fix: None needed; item is valid and accurate.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-004", "question": "A 2-month-old infant with congenital lymphocytic choriomeningitis virus (LCMV) infection presents with chorioretinitis, hydrocephalus, and periventricular calcifications. Which neuroimaging finding best distinguishes LCMV from congenital cytomegalovirus infection?", "options": ["Periventricular calcifications", "Cortical malformations", "Cerebellar hypoplasia", "Temporal lobe cysts", "Lissencephaly"], "answer": "C", "answer_index": 2, "explanation": "While both LCMV and CMV can cause periventricular calcifications, LCMV characteristically causes severe cerebellar hypoplasia due to selective infection of the external granular layer cells. CMV more commonly causes cortical malformations, temporal lobe cysts, and lissencephaly. This distinction is critical for prognosis and genetic counseling, as LCMV has a higher risk of severe neurodevelopmental disability.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: U (Underspecified, leading to M). Verdict: Not uniquely determinable. The question asks which neuroimaging finding \\\"best distinguishes\\\" LCMV from CMV in a patient already presenting with classic LCMV features. Key stem clues: 2-month-old with chorioretinitis, hydrocephalus, and periventricular calcifications—all consistent with congenital LCMV. The logical issue: the stem describes a patient with established LCMV infection, then asks what distinguishes it from CMV. This creates ambiguity about whether we're identifying features present in THIS patient versus general distinguishing features. Medical accuracy concerns: While cerebellar hypoplasia (C) is indeed associated with LCMV, the literature also describes cortical malformations (B) in LCMV cases, making both potentially defensible. The distinction between LCMV and CMV neuroimaging is not as clear-cut as implied; both can show overlapping features including periventricular calcifications, cortical abnormalities, and cerebellar involvement. The rationale overstates the specificity of cerebellar hypoplasia for LCMV. Temporal lobe cysts (D) and lissencephaly (E) are more characteristic of CMV but not universally present. Minimal fix: Rephrase to ask \\\"Which finding, if present, would most strongly suggest LCMV over CMV?\\\" and ensure options represent truly discriminating features with stronger evidence base.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (Underspecified, leading to M). Verdict: Not uniquely determinable. The question asks which neuroimaging finding \"best distinguishes\" LCMV from CMV in a patient already presenting with classic LCMV features. Key stem clues: 2-month-old with chorioretinitis, hydrocephalus, and periventricular calcifications—all consistent with congenital LCMV. The logical issue: the stem describes a patient with established LCMV infection, then asks what distinguishes it from CMV. This creates ambiguity about whether we're identifying features present in THIS patient versus general distinguishing features. Medical accuracy concerns: While cerebellar hypoplasia (C) is indeed associated with LCMV, the literature also describes cortical malformations (B) in LCMV cases, making both potentially defensible. The distinction between LCMV and CMV neuroimaging is not as clear-cut as implied; both can show overlapping features including periventricular calcifications, cortical abnormalities, and cerebellar involvement. The rationale overstates the specificity of cerebellar hypoplasia for LCMV. Temporal lobe cysts (D) and lissencephaly (E) are more characteristic of CMV but not universally present. Minimal fix: Rephrase to ask \"Which finding, if present, would most strongly suggest LCMV over CMV?\" and ensure options represent truly discriminating features with stronger evidence base.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-005", "question": "A 5-year-old boy with DOCK8 deficiency (biallelic null variants) has recurrent Staphylococcus aureus skin abscesses, severe eczema, and recurrent pneumonias. Which prophylactic regimen specifically targets the predominant immunologic defect?", "options": ["Trimethoprim-sulfamethoxazole for Pneumocystis prophylaxis", "Penicillin VK for streptococcal prophylaxis", "Itraconazole for fungal prophylaxis", "Azithromycin for atypical mycobacterial prophylaxis", "Valganciclovir for CMV prophylaxis"], "answer": "C", "answer_index": 2, "explanation": "DOCK8 deficiency is a combined immunodeficiency with impaired T-cell function leading to susceptibility to fungal infections, particularly Candida and dermatophytes. Itraconazole provides broad antifungal prophylaxis. TMP-SMX is for Pneumocystis but doesn't address the primary defect. Penicillin doesn't cover the main pathogens. Azithromycin is for atypical mycobacteria which are less common. Valganciclovir is for CMV which can occur but isn't the primary defect.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - the keyed answer does not match the predominant immunologic defect. Key stem clues: 5-year-old with DOCK8 deficiency presenting with recurrent S. aureus skin abscesses, severe eczema, and recurrent pneumonias. DOCK8 deficiency is a combined immunodeficiency characterized by defective T-cell and B-cell function, with a hallmark susceptibility to viral infections (especially cutaneous viral infections like molluscum, warts, HSV) and bacterial infections (particularly S. aureus). While fungal infections do occur, they are not the predominant feature. The clinical vignette emphasizes recurrent bacterial (S. aureus) infections. Main logical issue: The question asks for prophylaxis targeting the 'predominant immunologic defect,' but the keyed answer (C: Itraconazole) addresses fungal infections, which are not predominant in this presentation. The vignette's emphasis on S. aureus abscesses and pneumonias suggests bacterial infections are the primary concern. Main medical accuracy issue: The rationale incorrectly characterizes fungal infections as the primary defect in DOCK8 deficiency. While patients do get fungal infections, the predominant features are viral (especially cutaneous) and bacterial infections. Minimal fix: Either change the key to address bacterial prophylaxis or rewrite the vignette to emphasize fungal/viral manifestations typical of DOCK8 deficiency.\", \"medical_accuracy_score\": \"2\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - the keyed answer does not match the predominant immunologic defect. Key stem clues: 5-year-old with DOCK8 deficiency presenting with recurrent S. aureus skin abscesses, severe eczema, and recurrent pneumonias. DOCK8 deficiency is a combined immunodeficiency characterized by defective T-cell and B-cell function, with a hallmark susceptibility to viral infections (especially cutaneous viral infections like molluscum, warts, HSV) and bacterial infections (particularly S. aureus). While fungal infections do occur, they are not the predominant feature. The clinical vignette emphasizes recurrent bacterial (S. aureus) infections. Main logical issue: The question asks for prophylaxis targeting the 'predominant immunologic defect,' but the keyed answer (C: Itraconazole) addresses fungal infections, which are not predominant in this presentation. The vignette's emphasis on S. aureus abscesses and pneumonias suggests bacterial infections are the primary concern. Main medical accuracy issue: The rationale incorrectly characterizes fungal infections as the primary defect in DOCK8 deficiency. While patients do get fungal infections, the predominant features are viral (especially cutaneous) and bacterial infections. Minimal fix: Either change the key to address bacterial prophylaxis or rewrite the vignette to emphasize fungal/viral manifestations typical of DOCK8 deficiency.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-006", "question": "A 28-year-old male with a dibucaine number of 20 (normal >70) and pseudocholinesterase activity of 0.2 U/mL (normal 0.5-1.2) requires emergency intubation for airway obstruction. After succinylcholine 1.5 mg/kg, apnea persists for 90 minutes. Which anesthetic agent should be avoided in future surgeries due to shared metabolic pathway?", "options": ["Rocuronium", "Ester local anesthetics (procaine, chloroprocaine)", "Vecuronium", "Cisatracurium", "Remifentanil"], "answer": "B", "answer_index": 1, "explanation": "A dibucaine number of 20 indicates homozygous atypical pseudocholinesterase. Succinylcholine and ester local anesthetics (procaine, chloroprocaine, tetracaine) are both metabolized by pseudocholinesterase. Aminosteroid relaxants (rocuronium, vecuronium) and benzylisoquinoliniums (cisatracurium) are not metabolized by this enzyme. Remifentanil is metabolized by non-specific esterases and is safe.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Anesthesiology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a patient with homozygous atypical pseudocholinesterase deficiency (dibucaine number 20, normal >70; low enzyme activity). The prolonged apnea after succinylcholine confirms impaired metabolism via this pathway. The question asks which agent shares this metabolic pathway and should be avoided. Key discriminating findings: (1) dibucaine number 20 indicates homozygous atypical variant, (2) prolonged apnea post-succinylcholine, (3) pseudocholinesterase activity 0.2 U/mL (markedly reduced). Ester local anesthetics (procaine, chloroprocaine) are metabolized by pseudocholinesterase, making option B the correct answer. Alternatives: Rocuronium (A) and vecuronium (C) are aminosteroid neuromuscular blockers metabolized hepatically/renally, not by pseudocholinesterase. Cisatracurium (D) undergoes Hofmann elimination. Remifentanil (E) is metabolized by non-specific tissue esterases, not pseudocholinesterase. The item is logically valid with a unique best answer matching the key. Medical accuracy is high: the pathophysiology, enzyme deficiency classification, and drug metabolism pathways are correctly presented and clinically relevant. Minimal fix: None needed; item is well-constructed and unambiguous.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a patient with homozygous atypical pseudocholinesterase deficiency (dibucaine number 20, normal >70; low enzyme activity). The prolonged apnea after succinylcholine confirms impaired metabolism via this pathway. The question asks which agent shares this metabolic pathway and should be avoided. Key discriminating findings: (1) dibucaine number 20 indicates homozygous atypical variant, (2) prolonged apnea post-succinylcholine, (3) pseudocholinesterase activity 0.2 U/mL (markedly reduced). Ester local anesthetics (procaine, chloroprocaine) are metabolized by pseudocholinesterase, making option B the correct answer. Alternatives: Rocuronium (A) and vecuronium (C) are aminosteroid neuromuscular blockers metabolized hepatically/renally, not by pseudocholinesterase. Cisatracurium (D) undergoes Hofmann elimination. Remifentanil (E) is metabolized by non-specific tissue esterases, not pseudocholinesterase. The item is logically valid with a unique best answer matching the key. Medical accuracy is high: the pathophysiology, enzyme deficiency classification, and drug metabolism pathways are correctly presented and clinically relevant. Minimal fix: None needed; item is well-constructed and unambiguous.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-007", "question": "A 45-year-old male develops dyspnea 6 hours after interscalene brachial plexus block for shoulder surgery. Chest X-ray shows elevated right hemidiaphragm. Pulmonary function tests reveal: FVC 65% predicted, FEV1 70% predicted, FEV1/FVC 85%, TLC 70% predicted. Which PFT finding is most specific for phrenic nerve palsy versus other causes of dyspnea?", "options": ["Reduced FVC", "Preserved FEV1/FVC ratio", "Reduced TLC", "Paradoxical abdominal motion on examination", "Orthopnea"], "answer": "B", "answer_index": 1, "explanation": "Phrenic nerve palsy causes restrictive physiology with proportionate reduction in FVC and FEV1, preserving the FEV1/FVC ratio. Reduced TLC confirms restriction. While paradoxical abdominal motion is seen on examination, it is not a PFT finding. Orthopnea is nonspecific. The preserved ratio in context of reduced volumes is the key PFT pattern distinguishing restrictive from obstructive disease.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Anesthesiology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - a better answer exists. The question asks for the PFT finding \\\"most specific for phrenic nerve palsy versus other causes of dyspnea.\\\" Key stem clues: post-interscalene block timing (classic for phrenic nerve injury), elevated hemidiaphragm, restrictive pattern (FVC 65%, FEV1 70%, FEV1/FVC 85%, TLC 70%). The keyed answer (B: preserved FEV1/FVC ratio) indicates restrictive physiology but is NOT specific to phrenic nerve palsy - any restrictive process (ILD, chest wall disease, obesity) shows preserved ratio. Option C (reduced TLC) is the most specific PFT finding: in unilateral diaphragm paralysis, TLC reduction is disproportionately greater than FVC reduction due to loss of inspiratory muscle function and paradoxical diaphragm motion during inspiration. The stem shows TLC 70% vs FVC 65%, demonstrating this pattern. While preserved FEV1/FVC distinguishes restrictive from obstructive disease, it doesn't distinguish phrenic palsy from other restrictive causes. Medical accuracy: The physiology described is correct, but the key misidentifies which finding is most specific. Minimal fix: Change key to C, or reword question to ask which finding \\\"distinguishes restrictive from obstructive\\\" rather than \\\"most specific for phrenic nerve palsy.\\\"\", \"medical_accuracy_score\": \"4\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - a better answer exists. The question asks for the PFT finding \"most specific for phrenic nerve palsy versus other causes of dyspnea.\" Key stem clues: post-interscalene block timing (classic for phrenic nerve injury), elevated hemidiaphragm, restrictive pattern (FVC 65%, FEV1 70%, FEV1/FVC 85%, TLC 70%). The keyed answer (B: preserved FEV1/FVC ratio) indicates restrictive physiology but is NOT specific to phrenic nerve palsy - any restrictive process (ILD, chest wall disease, obesity) shows preserved ratio. Option C (reduced TLC) is the most specific PFT finding: in unilateral diaphragm paralysis, TLC reduction is disproportionately greater than FVC reduction due to loss of inspiratory muscle function and paradoxical diaphragm motion during inspiration. The stem shows TLC 70% vs FVC 65%, demonstrating this pattern. While preserved FEV1/FVC distinguishes restrictive from obstructive disease, it doesn't distinguish phrenic palsy from other restrictive causes. Medical accuracy: The physiology described is correct, but the key misidentifies which finding is most specific. Minimal fix: Change key to C, or reword question to ask which finding \"distinguishes restrictive from obstructive\" rather than \"most specific for phrenic nerve palsy.\"", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-008", "question": "A 22-year-old female with systemic lupus erythematosus presents with nihilistic delusions that her organs have 'turned to dust' and that she is already dead. CSF shows lymphocytic pleocytosis and elevated protein. Which specific autoantibody is most strongly associated with this neuropsychiatric manifestation?", "options": ["Anti-dsDNA", "Anti-NR2A (NMDA receptor)", "Anti-Ro/SSA", "Anti-phospholipid", "Anti-Sm"], "answer": "B", "answer_index": 1, "explanation": "Anti-NR2A antibodies targeting NMDA receptors correlate strongly with diffuse neuropsychiatric SLE manifestations including psychosis, delusional states, and cognitive dysfunction. Anti-dsDNA is a general SLE marker without specific neuropsychiatric correlation. Anti-Ro is associated with neonatal lupus. Antiphospholipid antibodies cause thrombotic events. Anti-Sm is specific for SLE but not associated with particular neuropsychiatric features.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: U (Underspecified) leading to M (Multiple answers defensible). Verdict: Not uniquely determinable. The vignette describes a 22-year-old SLE patient with Cotard delusion (nihilistic delusions of being dead/organs turned to dust) and CSF findings consistent with CNS inflammation (lymphocytic pleocytosis, elevated protein). The question asks which autoantibody is \\\"most strongly associated\\\" with this neuropsychiatric manifestation. Key issue: Anti-NR2A (anti-NMDA receptor) antibodies are indeed associated with neuropsychiatric SLE (NPSLE), particularly psychosis and cognitive dysfunction. However, anti-dsDNA antibodies also cross-react with NMDA receptors and are well-established in NPSLE pathogenesis, with strong evidence linking them to diffuse manifestations including psychosis. The stem does not provide discriminating details (e.g., specific antibody titers, response to immunotherapy, or other features) that would definitively favor anti-NR2A over anti-dsDNA. Both antibodies target NMDA receptors and correlate with psychotic NPSLE. The rationale dismisses anti-dsDNA as merely a \\\"general SLE marker,\\\" which understates its established role in NPSLE. Medical accuracy: The keyed answer reflects emerging research but oversimplifies the anti-dsDNA role. Minimal fix: Add discriminating clinical details or specify \\\"direct NMDA receptor antibody\\\" to uniquely support anti-NR2A, or acknowledge both mechanisms in the teaching point.\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (Underspecified) leading to M (Multiple answers defensible). Verdict: Not uniquely determinable. The vignette describes a 22-year-old SLE patient with Cotard delusion (nihilistic delusions of being dead/organs turned to dust) and CSF findings consistent with CNS inflammation (lymphocytic pleocytosis, elevated protein). The question asks which autoantibody is \"most strongly associated\" with this neuropsychiatric manifestation. Key issue: Anti-NR2A (anti-NMDA receptor) antibodies are indeed associated with neuropsychiatric SLE (NPSLE), particularly psychosis and cognitive dysfunction. However, anti-dsDNA antibodies also cross-react with NMDA receptors and are well-established in NPSLE pathogenesis, with strong evidence linking them to diffuse manifestations including psychosis. The stem does not provide discriminating details (e.g., specific antibody titers, response to immunotherapy, or other features) that would definitively favor anti-NR2A over anti-dsDNA. Both antibodies target NMDA receptors and correlate with psychotic NPSLE. The rationale dismisses anti-dsDNA as merely a \"general SLE marker,\" which understates its established role in NPSLE. Medical accuracy: The keyed answer reflects emerging research but oversimplifies the anti-dsDNA role. Minimal fix: Add discriminating clinical details or specify \"direct NMDA receptor antibody\" to uniquely support anti-NR2A, or acknowledge both mechanisms in the teaching point.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-009", "question": "A 35-year-old male with treatment-resistant schizophrenia is started on clozapine. He is HLA-DQB1*05:02 positive and HLA-B*38:02 negative. Which monitoring protocol is specifically indicated based on his genetic profile?", "options": ["Weekly CBC for 52 weeks, then monthly", "Weekly CBC for 26 weeks, then every 2 weeks to 52 weeks, then monthly", "Baseline CBC, then monthly only", "Weekly CBC for 6 months, then discontinue if stable", "No CBC monitoring required"], "answer": "B", "answer_index": 1, "explanation": "HLA-DQB1*05:02 is associated with increased clozapine-induced agranulocytosis risk, requiring extended intensive monitoring for 26 weeks before tapering frequency. HLA-B*38:02 is protective. Standard protocol is weekly for 6 months, but high-risk genotypes require longer intensive monitoring as per CPIC guidelines. Discontinuing monitoring or monthly-only monitoring is unsafe in this genetic context.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - the keyed answer contradicts established monitoring protocols. The stem describes a patient starting clozapine with HLA-DQB1*05:02 positive status (associated with increased agranulocytosis risk). Key discriminating finding: genetic risk marker present. The question asks for monitoring \\\"specifically indicated based on his genetic profile.\\\" However, current evidence and guidelines do NOT support genotype-specific clozapine monitoring protocols. The FDA-mandated REMS program requires: weekly CBC for 6 months, then biweekly for 6 months, then monthly - regardless of genetic status. CPIC guidelines acknowledge HLA associations but do NOT recommend altering the standard monitoring schedule based on genotype. Option B (26 weeks weekly, then biweekly to 52 weeks, then monthly) does not match any established protocol. Option A more closely approximates standard monitoring (though still imprecise). The item's premise that genetic profile dictates a specific monitoring protocol is medically inaccurate. Main logical issue: the keyed answer describes a non-existent protocol. Main medical accuracy issue: conflates research associations with clinical practice guidelines. Minimal fix: Remove genetic information and ask for standard clozapine monitoring protocol, with Option A adjusted to match FDA REMS requirements exactly.\", \"medical_accuracy_score\": \"2\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - the keyed answer contradicts established monitoring protocols. The stem describes a patient starting clozapine with HLA-DQB1*05:02 positive status (associated with increased agranulocytosis risk). Key discriminating finding: genetic risk marker present. The question asks for monitoring \"specifically indicated based on his genetic profile.\" However, current evidence and guidelines do NOT support genotype-specific clozapine monitoring protocols. The FDA-mandated REMS program requires: weekly CBC for 6 months, then biweekly for 6 months, then monthly - regardless of genetic status. CPIC guidelines acknowledge HLA associations but do NOT recommend altering the standard monitoring schedule based on genotype. Option B (26 weeks weekly, then biweekly to 52 weeks, then monthly) does not match any established protocol. Option A more closely approximates standard monitoring (though still imprecise). The item's premise that genetic profile dictates a specific monitoring protocol is medically inaccurate. Main logical issue: the keyed answer describes a non-existent protocol. Main medical accuracy issue: conflates research associations with clinical practice guidelines. Minimal fix: Remove genetic information and ask for standard clozapine monitoring protocol, with Option A adjusted to match FDA REMS requirements exactly.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-010", "question": "A 7-year-old boy presents with 18-month history of progressive social withdrawal, flattened affect, disorganized speech, and tactile hallucinations of 'bugs crawling under my skin.' He has no prior developmental delays. Which specific prodromal feature best predicts conversion to definitive schizophrenia in children?", "options": ["Social isolation", "Flattened affect", "Disorganized speech", "Tactile hallucinations", "Decline in academic performance"], "answer": "D", "answer_index": 3, "explanation": "While social isolation and affective flattening are common prodromal symptoms, tactile hallucinations are uncommon in childhood and strongly predict conversion to schizophrenia spectrum disorders. Auditory hallucinations are more frequent but less specific. The presence of multimodal hallucinations, particularly somatic/tactile, increases risk substantially and warrants aggressive early intervention.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: U (Underspecified) leading to M (Multiple answers defensible). Verdict: Not uniquely determinable. The question asks which prodromal feature \\\"best predicts conversion\\\" to schizophrenia in children, but the vignette describes a child already exhibiting active psychotic symptoms (hallucinations, disorganized speech, flattened affect) over 18 months—this represents manifest illness, not prodrome. The term \\\"prodromal\\\" refers to pre-psychotic attenuated symptoms, yet the child has frank psychosis. This temporal/definitional confusion undermines the question's premise. Key stem clues: 18-month progressive course with hallucinations and disorganized speech suggests established psychotic disorder. Main logical issue: The question conflates prodromal (pre-psychotic) features with active psychotic symptoms. Without clarifying whether we're identifying predictors from an actual prodromal phase or rating symptom severity in established illness, multiple answers become defensible. Social isolation (A) and decline in academic performance (E) are well-documented early prodromal markers; tactile hallucinations (D), while unusual, represent active psychosis rather than prodrome. Medical accuracy issue: The rationale's claim that tactile hallucinations specifically predict conversion lacks strong pediatric evidence; most literature emphasizes negative symptoms and functional decline as prodromal predictors. Minimal fix: Reframe as \\\"Which symptom in this presentation is most specific for childhood-onset schizophrenia?\\\" or clarify a true prodromal timeline before psychosis onset.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (Underspecified) leading to M (Multiple answers defensible). Verdict: Not uniquely determinable. The question asks which prodromal feature \"best predicts conversion\" to schizophrenia in children, but the vignette describes a child already exhibiting active psychotic symptoms (hallucinations, disorganized speech, flattened affect) over 18 months—this represents manifest illness, not prodrome. The term \"prodromal\" refers to pre-psychotic attenuated symptoms, yet the child has frank psychosis. This temporal/definitional confusion undermines the question's premise. Key stem clues: 18-month progressive course with hallucinations and disorganized speech suggests established psychotic disorder. Main logical issue: The question conflates prodromal (pre-psychotic) features with active psychotic symptoms. Without clarifying whether we're identifying predictors from an actual prodromal phase or rating symptom severity in established illness, multiple answers become defensible. Social isolation (A) and decline in academic performance (E) are well-documented early prodromal markers; tactile hallucinations (D), while unusual, represent active psychosis rather than prodrome. Medical accuracy issue: The rationale's claim that tactile hallucinations specifically predict conversion lacks strong pediatric evidence; most literature emphasizes negative symptoms and functional decline as prodromal predictors. Minimal fix: Reframe as \"Which symptom in this presentation is most specific for childhood-onset schizophrenia?\" or clarify a true prodromal timeline before psychosis onset.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-011", "question": "A 14-year-old female presents with fever, weight loss, claudication in left arm, and blood pressure discrepancy of 30 mmHg between arms. MRA shows stenosis of left subclavian artery and abdominal aorta. According to childhood Takayasu arteritis criteria, which additional finding is required for definitive diagnosis?", "options": ["Elevated ESR >40 mm/hr", "Positive ANA titer >1:320", "Stenosis of >3 vascular territories", "Presence of pulmonary artery involvement", "Age at diagnosis <16 years"], "answer": "C", "answer_index": 2, "explanation": "Childhood Takayasu arteritis per EULAR/PRINTO criteria requires angiographic abnormalities plus either typical symptoms or elevated inflammatory markers, AND involvement of >3 vascular territories. Adult criteria are less stringent. Pulmonary artery involvement is supportive but not required. Age is part of classification but not a diagnostic criterion. ANA positivity is not required.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: U (Underspecified) leading to potential M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a 14-year-old with fever, weight loss, claudication, BP discrepancy, and MRA showing stenosis of left subclavian artery and abdominal aorta—classic Takayasu arteritis features. The question asks what additional finding is required for definitive diagnosis per childhood criteria. Key stem clues: age <16, systemic symptoms, BP discrepancy, and 2 documented vascular territories (subclavian + abdominal aorta). The keyed answer C (>3 vascular territories) aligns with EULAR/PRINTO/PRES 2010 criteria requiring angiographic abnormality in ≥1 of 5 territories PLUS ≥1 of 5 clinical/lab criteria. However, the stem is underspecified: it doesn't clarify whether the patient already meets the clinical criteria component (fever/weight loss may suffice as systemic features). If clinical criteria are met, then only the angiographic threshold matters; if not, elevated ESR (option A) could also be required. The rationale correctly notes >3 territories but doesn't address whether inflammatory markers are simultaneously needed. Main logical issue: ambiguity about which diagnostic component is missing. Main medical accuracy issue: the criteria require angiographic abnormality PLUS clinical/lab features; the stem doesn't confirm both are satisfied. Minimal fix: explicitly state 'Patient meets clinical criteria; what angiographic finding completes diagnosis?'\",\"medical_accuracy_score\":\"4\",\"logical_validity\":false,\"logical_false_reason\":\"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (Underspecified) leading to potential M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a 14-year-old with fever, weight loss, claudication, BP discrepancy, and MRA showing stenosis of left subclavian artery and abdominal aorta—classic Takayasu arteritis features. The question asks what additional finding is required for definitive diagnosis per childhood criteria. Key stem clues: age <16, systemic symptoms, BP discrepancy, and 2 documented vascular territories (subclavian + abdominal aorta). The keyed answer C (>3 vascular territories) aligns with EULAR/PRINTO/PRES 2010 criteria requiring angiographic abnormality in ≥1 of 5 territories PLUS ≥1 of 5 clinical/lab criteria. However, the stem is underspecified: it doesn't clarify whether the patient already meets the clinical criteria component (fever/weight loss may suffice as systemic features). If clinical criteria are met, then only the angiographic threshold matters; if not, elevated ESR (option A) could also be required. The rationale correctly notes >3 territories but doesn't address whether inflammatory markers are simultaneously needed. Main logical issue: ambiguity about which diagnostic component is missing. Main medical accuracy issue: the criteria require angiographic abnormality PLUS clinical/lab features; the stem doesn't confirm both are satisfied. Minimal fix: explicitly state 'Patient meets clinical criteria; what angiographic finding completes diagnosis?'", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-012", "question": "A 3-week-old neonate presents with intractable seizures unresponsive to phenobarbital and levetiracetam. EEG shows burst-suppression pattern. CSF neurotransmitter analysis shows elevated 3-methoxy-4-hydroxyphenylglycol (MHPG) and reduced homovanillic acid (HVA). Which specific enzyme deficiency is suggested by this pattern?", "options": ["Pyridoxine 5'-phosphate oxidase", "GABA transaminase", "Aromatic L-amino acid decarboxylase", "Pyridoxal kinase", "Succinic semialdehyde dehydrogenase"], "answer": "A", "answer_index": 0, "explanation": "Pyridoxine 5'-phosphate oxidase (PNPO) deficiency impairs conversion of pyridoxine 5'-phosphate to pyridoxal 5'-phosphate, the active cofactor for GABA synthesis. CSF shows elevated MHPG/HVA ratio >2.5, which is pathognomonic. AADC deficiency shows reduced HVA and 5-HIAA. Pyridoxal kinase deficiency has different metabolite ratios. SSADH deficiency shows elevated GABA.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: K (Miskeyed). Verdict: The keyed answer (A, PNPO deficiency) is incorrect; the correct answer is C (AADC deficiency). Key stem clues: elevated MHPG (norepinephrine metabolite) with reduced HVA (dopamine metabolite) in a neonate with intractable seizures and burst-suppression EEG. Main logical issue: The CSF pattern described—elevated MHPG with reduced HVA—is pathognomonic for aromatic L-amino acid decarboxylase (AADC) deficiency, not PNPO deficiency. AADC catalyzes conversion of L-DOPA to dopamine and 5-HTP to serotonin; its deficiency causes reduced dopamine/serotonin metabolites (low HVA, low 5-HIAA) with accumulation of precursors and alternative metabolites like MHPG. PNPO deficiency typically shows elevated vanillactate and 3-methoxytyrosine, with an elevated MHPG/HVA ratio, but the absolute reduction in HVA is more characteristic of AADC deficiency. The author's rationale incorrectly attributes the elevated MHPG/reduced HVA pattern to PNPO and contradicts itself by stating AADC shows reduced HVA. Medical accuracy issue: The metabolite pattern assignment is reversed. Minimal fix: Change the correct answer key from A to C, or modify the CSF findings to match PNPO deficiency (elevated vanillactate, 3-methoxytyrosine).\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: The keyed answer (A, PNPO deficiency) is incorrect; the correct answer is C (AADC deficiency). Key stem clues: elevated MHPG (norepinephrine metabolite) with reduced HVA (dopamine metabolite) in a neonate with intractable seizures and burst-suppression EEG. Main logical issue: The CSF pattern described—elevated MHPG with reduced HVA—is pathognomonic for aromatic L-amino acid decarboxylase (AADC) deficiency, not PNPO deficiency. AADC catalyzes conversion of L-DOPA to dopamine and 5-HTP to serotonin; its deficiency causes reduced dopamine/serotonin metabolites (low HVA, low 5-HIAA) with accumulation of precursors and alternative metabolites like MHPG. PNPO deficiency typically shows elevated vanillactate and 3-methoxytyrosine, with an elevated MHPG/HVA ratio, but the absolute reduction in HVA is more characteristic of AADC deficiency. The author's rationale incorrectly attributes the elevated MHPG/reduced HVA pattern to PNPO and contradicts itself by stating AADC shows reduced HVA. Medical accuracy issue: The metabolite pattern assignment is reversed. Minimal fix: Change the correct answer key from A to C, or modify the CSF findings to match PNPO deficiency (elevated vanillactate, 3-methoxytyrosine).", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-013", "question": "A 2-month-old infant presents with heart failure, mitral regurgitation, and echocardiographic finding of retrograde flow in a dilated left coronary artery during diastole. Which additional echocardiographic finding is pathognomonic for anomalous left coronary artery from pulmonary artery (ALCAPA)?", "options": ["Left ventricular dilation", "Papillary muscle dysfunction", "Septal wall motion abnormalities", "Coronary artery collaterals with 'seagull' sign", "Right coronary artery dilation"], "answer": "D", "answer_index": 3, "explanation": "In ALCAPA, extensive intercoronary collaterals develop with characteristic bidirectional flow seen on color Doppler as a 'seagull' sign. While LV dilation, papillary muscle dysfunction, and RCA dilation are seen, they are not pathognomonic. The seagull sign represents collaterals from RCA to LCA with flow reversal into PA, which is diagnostic of ALCAPA.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 2-month-old with heart failure, mitral regurgitation, and retrograde diastolic flow in a dilated left coronary artery—classic ALCAPA presentation. The question asks for a pathognomonic echocardiographic finding. Key discriminating clue: 'pathognomonic' demands a finding specific to ALCAPA, not merely associated features. Option D (coronary collaterals with 'seagull' sign) is correct—this Doppler pattern showing bidirectional flow through RCA-to-LCA collaterals with flow reversal into the pulmonary artery is diagnostic and specific for ALCAPA's steal physiology. Options A, B, C, and E (LV dilation, papillary muscle dysfunction, septal wall motion abnormalities, RCA dilation) are all seen in ALCAPA but are nonspecific consequences of ischemia/volume overload and occur in other conditions. The stem provides sufficient information to identify ALCAPA and select the pathognomonic finding. Medical accuracy: The seagull sign is well-established in pediatric cardiology literature as characteristic of ALCAPA's collateral flow pattern. No logical flaws or missing critical details. Minimal fix: None needed; item is valid and accurate.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 2-month-old with heart failure, mitral regurgitation, and retrograde diastolic flow in a dilated left coronary artery—classic ALCAPA presentation. The question asks for a pathognomonic echocardiographic finding. Key discriminating clue: 'pathognomonic' demands a finding specific to ALCAPA, not merely associated features. Option D (coronary collaterals with 'seagull' sign) is correct—this Doppler pattern showing bidirectional flow through RCA-to-LCA collaterals with flow reversal into the pulmonary artery is diagnostic and specific for ALCAPA's steal physiology. Options A, B, C, and E (LV dilation, papillary muscle dysfunction, septal wall motion abnormalities, RCA dilation) are all seen in ALCAPA but are nonspecific consequences of ischemia/volume overload and occur in other conditions. The stem provides sufficient information to identify ALCAPA and select the pathognomonic finding. Medical accuracy: The seagull sign is well-established in pediatric cardiology literature as characteristic of ALCAPA's collateral flow pattern. No logical flaws or missing critical details. Minimal fix: None needed; item is valid and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-014", "question": "A 3-week-old neonate presents with watery diarrhea, dehydration, and metabolic alkalosis. Stool chloride is 120 mEq/L (normal <20). Genetic testing confirms CLCN5 mutation. Which electrolyte pattern is most specific for congenital chloride diarrhea versus other causes of neonatal secretory diarrhea?", "options": ["Hypochloremia, hyponatremia, metabolic alkalosis", "Hypochloremia, hyponatremia, metabolic acidosis", "Hyperchloremia, hypernatremia, metabolic alkalosis", "Hyperchloremia, hyponatremia, metabolic alkalosis", "Normal chloride, hyponatremia, metabolic acidosis"], "answer": "A", "answer_index": 0, "explanation": "CLCN5 mutation impairs ileal chloride-bicarbonate exchange, causing massive chloride loss, hypochloremia, and secondary metabolic alkalosis. Hyponatremia occurs from volume contraction. This contrasts with other secretory diarrheas which typically cause metabolic acidosis. Stool chloride >90 mEq/L is diagnostic and distinguishes it from other causes.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - the correct answer should be A, but the genetic/clinical information contains a critical error. Key stem clues: 3-week-old with watery diarrhea, dehydration, metabolic alkalosis, stool chloride 120 mEq/L (highly elevated). Main logical issue: The stem states 'CLCN5 mutation' but congenital chloride diarrhea (CCD) is caused by SLC26A3 mutation, not CLCN5. CLCN5 mutations cause Dent disease (renal tubular disorder), not intestinal chloride transport defects. This is a fundamental medical error that undermines the question's validity. Main medical accuracy issue: The gene-disease pairing is incorrect. CCD results from defective SLC26A3 (DRA - downregulated in adenoma), which encodes the ileal Cl-/HCO3- exchanger. The pathophysiology described (impaired ileal chloride-bicarbonate exchange, massive chloride loss, hypochloremia, metabolic alkalosis) is correct for CCD, and option A correctly identifies the electrolyte pattern. However, attributing this to CLCN5 is medically inaccurate. Minimal fix: Change 'CLCN5 mutation' to 'SLC26A3 mutation' in the stem. With this correction, the item would be valid (V) as option A would be the unique best answer supported by the clinical presentation and pathophysiology of congenital chloride diarrhea.\", \"medical_accuracy_score\": \"2\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - the correct answer should be A, but the genetic/clinical information contains a critical error. Key stem clues: 3-week-old with watery diarrhea, dehydration, metabolic alkalosis, stool chloride 120 mEq/L (highly elevated). Main logical issue: The stem states 'CLCN5 mutation' but congenital chloride diarrhea (CCD) is caused by SLC26A3 mutation, not CLCN5. CLCN5 mutations cause Dent disease (renal tubular disorder), not intestinal chloride transport defects. This is a fundamental medical error that undermines the question's validity. Main medical accuracy issue: The gene-disease pairing is incorrect. CCD results from defective SLC26A3 (DRA - downregulated in adenoma), which encodes the ileal Cl-/HCO3- exchanger. The pathophysiology described (impaired ileal chloride-bicarbonate exchange, massive chloride loss, hypochloremia, metabolic alkalosis) is correct for CCD, and option A correctly identifies the electrolyte pattern. However, attributing this to CLCN5 is medically inaccurate. Minimal fix: Change 'CLCN5 mutation' to 'SLC26A3 mutation' in the stem. With this correction, the item would be valid (V) as option A would be the unique best answer supported by the clinical presentation and pathophysiology of congenital chloride diarrhea.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-015", "question": "A 6-year-old boy presents with low molecular weight proteinuria, hypercalciuria, and nephrocalcinosis. Genetic testing confirms OCRL1 mutation (Dent disease type 2). Which specific tubular transport defect is characteristic of Dent disease?", "options": ["Proximal tubular phosphate reabsorption defect", "Proximal tubular glucose reabsorption defect", "Loop of Henle chloride reabsorption defect", "Distal tubular proton secretion defect", "Collecting duct water reabsorption defect"], "answer": "A", "answer_index": 0, "explanation": "Dent disease is caused by OCRL1 or CLCN5 mutations affecting proximal tubular endocytosis via the megalin/cubilin pathway, causing low molecular weight proteinuria, hypercalciuria, and phosphate wasting. It does not primarily affect glucose, chloride, proton, or water transport. The proximal tubular phosphate defect distinguishes it from other tubular disorders.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - the keyed answer does not match the best answer supported by the vignette. The stem describes a 6-year-old with low molecular weight (LMW) proteinuria, hypercalciuria, and nephrocalcinosis with confirmed OCRL1 mutation (Dent disease type 2). The question asks for the 'characteristic' tubular transport defect. Key stem clues: LMW proteinuria is the hallmark finding that defines Dent disease and results from defective proximal tubular endocytosis via the megalin/cubilin pathway. While phosphate wasting does occur in Dent disease, it is not the primary or most characteristic defect - it is secondary to the endocytic dysfunction. The most characteristic defect is impaired proximal tubular protein reabsorption (endocytosis), which is not offered as an option. Among the given choices, option A (phosphate reabsorption defect) is the most defensible as it does occur in Dent disease, but calling it 'characteristic' is medically imprecise since LMW proteinuria from endocytic defects is the defining feature. The item is logically flawed because the truly characteristic defect (protein/endocytic) is absent from options. Medical accuracy issue: conflating a secondary manifestation (phosphate wasting) with the primary characteristic defect (endocytosis). Minimal fix: Add option for 'Proximal tubular protein endocytosis defect' or rephrase question to ask about 'associated' rather than 'characteristic' defect.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - the keyed answer does not match the best answer supported by the vignette. The stem describes a 6-year-old with low molecular weight (LMW) proteinuria, hypercalciuria, and nephrocalcinosis with confirmed OCRL1 mutation (Dent disease type 2). The question asks for the 'characteristic' tubular transport defect. Key stem clues: LMW proteinuria is the hallmark finding that defines Dent disease and results from defective proximal tubular endocytosis via the megalin/cubilin pathway. While phosphate wasting does occur in Dent disease, it is not the primary or most characteristic defect - it is secondary to the endocytic dysfunction. The most characteristic defect is impaired proximal tubular protein reabsorption (endocytosis), which is not offered as an option. Among the given choices, option A (phosphate reabsorption defect) is the most defensible as it does occur in Dent disease, but calling it 'characteristic' is medically imprecise since LMW proteinuria from endocytic defects is the defining feature. The item is logically flawed because the truly characteristic defect (protein/endocytic) is absent from options. Medical accuracy issue: conflating a secondary manifestation (phosphate wasting) with the primary characteristic defect (endocytosis). Minimal fix: Add option for 'Proximal tubular protein endocytosis defect' or rephrase question to ask about 'associated' rather than 'characteristic' defect.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-016", "question": "A 6-year-old child with CYP2D6 ultra-rapid metabolizer genotype (gene duplication) undergoes tonsillectomy. Postoperatively, he receives codeine 1 mg/kg q6h for pain. Which specific monitoring parameter is most critical in the first 24 hours to detect opioid toxicity?", "options": ["Respiratory rate every 4 hours", "Continuous pulse oximetry for 24 hours", "Pain score assessment every 2 hours", "Sedation score every hour for 8 hours", "Capnography for 12 hours"], "answer": "B", "answer_index": 1, "explanation": "CYP2D6 ultra-rapid metabolizers convert codeine to morphine at rates 2-10x normal, causing unpredictable and life-threatening respiratory depression. The FDA specifically contraindicates codeine in these children post-tonsillectomy. Continuous pulse oximetry is most sensitive for detecting early respiratory depression. Sedation scores are less reliable. Capnography is not standard of care.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Anesthesiology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - a better answer exists. The stem describes a CYP2D6 ultra-rapid metabolizer receiving codeine post-tonsillectomy, creating high risk for rapid morphine accumulation and respiratory depression. Key discriminating findings: (1) ultra-rapid metabolizer genotype with gene duplication, (2) post-tonsillectomy setting (OSA risk), (3) codeine dosing that will produce excessive morphine. The question asks for the MOST CRITICAL monitoring parameter to detect opioid toxicity in first 24 hours. While continuous pulse oximetry (B, the key) detects hypoxemia, it is a late sign of respiratory depression. Sedation precedes respiratory depression in opioid toxicity progression. Option D (sedation score every hour for 8 hours) provides more frequent assessment (hourly vs intermittent SpO2 checks) of an earlier warning sign. However, D's 8-hour duration is problematic when the question specifies 24-hour monitoring. The fundamental issue: FDA guidance actually contraindicates codeine entirely in this population post-tonsillectomy, making the clinical scenario itself problematic. Among monitoring options, continuous pulse oximetry vs hourly sedation scoring represents M (multiple defensible answers) based on detection sensitivity vs warning timeline trade-offs. Medical accuracy issue: presenting a contraindicated scenario without acknowledging the contraindication. Minimal fix: Either change to 'if codeine were inadvertently given' or ask about prevention rather than monitoring.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - a better answer exists. The stem describes a CYP2D6 ultra-rapid metabolizer receiving codeine post-tonsillectomy, creating high risk for rapid morphine accumulation and respiratory depression. Key discriminating findings: (1) ultra-rapid metabolizer genotype with gene duplication, (2) post-tonsillectomy setting (OSA risk), (3) codeine dosing that will produce excessive morphine. The question asks for the MOST CRITICAL monitoring parameter to detect opioid toxicity in first 24 hours. While continuous pulse oximetry (B, the key) detects hypoxemia, it is a late sign of respiratory depression. Sedation precedes respiratory depression in opioid toxicity progression. Option D (sedation score every hour for 8 hours) provides more frequent assessment (hourly vs intermittent SpO2 checks) of an earlier warning sign. However, D's 8-hour duration is problematic when the question specifies 24-hour monitoring. The fundamental issue: FDA guidance actually contraindicates codeine entirely in this population post-tonsillectomy, making the clinical scenario itself problematic. Among monitoring options, continuous pulse oximetry vs hourly sedation scoring represents M (multiple defensible answers) based on detection sensitivity vs warning timeline trade-offs. Medical accuracy issue: presenting a contraindicated scenario without acknowledging the contraindication. Minimal fix: Either change to 'if codeine were inadvertently given' or ask about prevention rather than monitoring.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-017", "question": "A 30-year-old female with acute intermittent porphyria requires general anesthesia for laparoscopic cholecystectomy. Which anesthetic agent is specifically contraindicated due to its porphyrinogenic effect?", "options": ["Propofol", "Sevoflurane", "Etomidate", "Thiopental", "Desflurane"], "answer": "D", "answer_index": 3, "explanation": "Barbiturates like thiopental are absolutely contraindicated in acute porphyrias as they strongly induce hepatic ALA synthase, triggering life-threatening attacks. Propofol, etomidate, and volatile agents (sevoflurane, desflurane) are considered safe. The question tests knowledge of specific porphyrinogenic drugs that must be avoided in this population.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Anesthesiology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem presents a 30-year-old female with acute intermittent porphyria (AIP) requiring general anesthesia, asking which agent is specifically contraindicated due to porphyrinogenic effects. Key discriminating finding: AIP diagnosis requiring anesthetic selection. Thiopental (D) is the keyed answer and is medically correct—barbiturates are absolutely contraindicated in acute porphyrias because they induce hepatic δ-aminolevulinic acid (ALA) synthase, precipitating potentially fatal acute attacks. Propofol (A) is considered safe and is the preferred induction agent in AIP. Sevoflurane (B) and desflurane (E) are volatile anesthetics deemed safe in porphyria. Etomidate (C) is generally considered safe, though less commonly used than propofol. The question clearly identifies one uniquely contraindicated agent among safe alternatives, making it logically valid with strong discriminatory power. Medical accuracy is excellent—aligns with current anesthesia guidelines for porphyria management. No logical flaws or medical inaccuracies detected. The item effectively tests critical drug-safety knowledge relevant to perioperative care. Minimal fix: None needed; item is well-constructed and unambiguous.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem presents a 30-year-old female with acute intermittent porphyria (AIP) requiring general anesthesia, asking which agent is specifically contraindicated due to porphyrinogenic effects. Key discriminating finding: AIP diagnosis requiring anesthetic selection. Thiopental (D) is the keyed answer and is medically correct—barbiturates are absolutely contraindicated in acute porphyrias because they induce hepatic δ-aminolevulinic acid (ALA) synthase, precipitating potentially fatal acute attacks. Propofol (A) is considered safe and is the preferred induction agent in AIP. Sevoflurane (B) and desflurane (E) are volatile anesthetics deemed safe in porphyria. Etomidate (C) is generally considered safe, though less commonly used than propofol. The question clearly identifies one uniquely contraindicated agent among safe alternatives, making it logically valid with strong discriminatory power. Medical accuracy is excellent—aligns with current anesthesia guidelines for porphyria management. No logical flaws or medical inaccuracies detected. The item effectively tests critical drug-safety knowledge relevant to perioperative care. Minimal fix: None needed; item is well-constructed and unambiguous.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-018", "question": "A 28-year-old female with SLE presents with psychosis, catatonia, and seizures. CSF shows anti-NR2A antibodies. Which specific immunosuppressive regimen is most effective for antibody-mediated neuropsychiatric SLE?", "options": ["High-dose steroids alone", "Cyclophosphamide 500 mg/m² monthly", "Rituximab 375 mg/m² weekly × 4 plus high-dose steroids", "Mycophenolate mofetil 2 g daily", "Intravenous immunoglobulin 2 g/kg monthly"], "answer": "C", "answer_index": 2, "explanation": "Anti-NR2A antibody-mediated neuropsychiatric SLE requires B-cell depletion with rituximab plus high-dose steroids. Steroids alone are insufficient. Cyclophosphamide is less effective for antibody-mediated disease. Mycophenolate is maintenance therapy. IVIG is adjunctive. The combination of rituximab and steroids provides rapid clearance of pathogenic antibodies.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: U (Underspecified) leading to M (Multiple answers defensible). Verdict: Not uniquely determinable. The vignette describes severe neuropsychiatric SLE (NPSLE) with anti-NR2A antibodies, psychosis, catatonia, and seizures. Key discriminating findings include the antibody-mediated mechanism and severe presentation. However, the item is underspecified because it lacks critical details about disease severity staging, prior treatment failures, and refractory status. The keyed answer (C: rituximab plus steroids) assumes refractory antibody-mediated disease requiring B-cell depletion, but this is not explicitly stated. Option B (cyclophosphamide) is equally defensible for severe NPSLE per ACR guidelines and multiple studies showing efficacy in refractory cases. The stem does not specify why rituximab would be preferred over cyclophosphamide for this presentation. Medical accuracy issues: The explanation oversimplifies by stating cyclophosphamide is 'less effective for antibody-mediated disease'—both agents are used for severe NPSLE, with choice depending on specific clinical context, prior treatments, and institutional protocols. The evidence base for rituximab superiority in antibody-mediated NPSLE is not as definitive as implied. Minimal fix: Add 'refractory to initial cyclophosphamide therapy' or specify 'anti-B-cell therapy preferred' to justify rituximab uniquely.\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (Underspecified) leading to M (Multiple answers defensible). Verdict: Not uniquely determinable. The vignette describes severe neuropsychiatric SLE (NPSLE) with anti-NR2A antibodies, psychosis, catatonia, and seizures. Key discriminating findings include the antibody-mediated mechanism and severe presentation. However, the item is underspecified because it lacks critical details about disease severity staging, prior treatment failures, and refractory status. The keyed answer (C: rituximab plus steroids) assumes refractory antibody-mediated disease requiring B-cell depletion, but this is not explicitly stated. Option B (cyclophosphamide) is equally defensible for severe NPSLE per ACR guidelines and multiple studies showing efficacy in refractory cases. The stem does not specify why rituximab would be preferred over cyclophosphamide for this presentation. Medical accuracy issues: The explanation oversimplifies by stating cyclophosphamide is 'less effective for antibody-mediated disease'—both agents are used for severe NPSLE, with choice depending on specific clinical context, prior treatments, and institutional protocols. The evidence base for rituximab superiority in antibody-mediated NPSLE is not as definitive as implied. Minimal fix: Add 'refractory to initial cyclophosphamide therapy' or specify 'anti-B-cell therapy preferred' to justify rituximab uniquely.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-019", "question": "A 78-year-old female with major depressive disorder is started on sertraline 50 mg daily. She has SIADH risk factors: age >65, female, concomitant thiazide diuretic. Which electrolyte monitoring protocol is recommended?", "options": ["Baseline sodium only", "Baseline and 1-week sodium", "Baseline, 1-week, and 2-week sodium", "Baseline, 1-week, 2-week, and 4-week sodium", "Weekly sodium for 8 weeks"], "answer": "D", "answer_index": 3, "explanation": "SIADH from SSRIs typically occurs within 2-4 weeks. High-risk patients (elderly, female, diuretic use) require sodium monitoring at baseline, 1, 2, and 4 weeks. More frequent monitoring is unnecessary if stable. Baseline alone or single follow-up is insufficient. Weekly monitoring for 8 weeks is excessive and not guideline-recommended.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: U (Underspecified) leading to M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem asks for the \\\"recommended\\\" monitoring protocol for SSRI-induced hyponatremia in a high-risk patient but provides no source guideline. Key stem clues: 78-year-old female, sertraline initiation, three SIADH risk factors (age, sex, thiazide). The rationale states \\\"guideline-recommended\\\" but no actual guideline mandates the specific D schedule (baseline, 1, 2, 4 weeks). Major logical issue: Without citing a specific authoritative source, \\\"recommended\\\" is ambiguous. Various expert opinions suggest monitoring at 1-2 weeks and 4 weeks for high-risk patients, but no universal standard exists. Options C (baseline, 1, 2 weeks) and D differ only by the 4-week check; both are clinically reasonable. Option E (weekly×8) is more intensive but not clearly wrong for very high-risk patients. Medical accuracy: The teaching point (monitor high-risk patients more than baseline alone) is sound, and SIADH typically occurs within 2-4 weeks. However, asserting D as the unique \\\"recommended\\\" protocol overstates guideline specificity. Minimal fix: Specify \\\"According to [named guideline/consensus], which monitoring schedule is recommended?\\\" or reframe as \\\"most appropriate\\\" with clinical context favoring one interval over another.\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (Underspecified) leading to M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem asks for the \"recommended\" monitoring protocol for SSRI-induced hyponatremia in a high-risk patient but provides no source guideline. Key stem clues: 78-year-old female, sertraline initiation, three SIADH risk factors (age, sex, thiazide). The rationale states \"guideline-recommended\" but no actual guideline mandates the specific D schedule (baseline, 1, 2, 4 weeks). Major logical issue: Without citing a specific authoritative source, \"recommended\" is ambiguous. Various expert opinions suggest monitoring at 1-2 weeks and 4 weeks for high-risk patients, but no universal standard exists. Options C (baseline, 1, 2 weeks) and D differ only by the 4-week check; both are clinically reasonable. Option E (weekly×8) is more intensive but not clearly wrong for very high-risk patients. Medical accuracy: The teaching point (monitor high-risk patients more than baseline alone) is sound, and SIADH typically occurs within 2-4 weeks. However, asserting D as the unique \"recommended\" protocol overstates guideline specificity. Minimal fix: Specify \"According to [named guideline/consensus], which monitoring schedule is recommended?\" or reframe as \"most appropriate\" with clinical context favoring one interval over another.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-020", "question": "A 35-year-old male in a personal injury lawsuit reports severe chronic pain despite normal examinations and imaging. He is observed to be inconsistent in his symptom presentation between evaluations. Which specific criterion best distinguishes malingering from factitious disorder in this scenario?", "options": ["Presence of secondary gain", "Intentional production of symptoms", "Lack of insight into psychological factors", "Symptoms are under voluntary control", "Absence of medical explanation"], "answer": "A", "answer_index": 0, "explanation": "Both malingering and factitious disorder involve intentional symptom production. The key distinction is motivation: malingering seeks external reward (money, avoiding work), while factitious disorder seeks the 'sick role' for psychological needs. Both have insight and voluntary control. Absence of medical explanation is common to both somatic symptom disorders.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a patient in a personal injury lawsuit with inconsistent symptom presentation despite normal findings—classic malingering context. Key discriminating clues: (1) personal injury lawsuit context, (2) inconsistent presentations, (3) normal objective findings. The question asks what BEST DISTINGUISHES malingering from factitious disorder. Option A (secondary gain) is correct: malingering involves external incentives (lawsuit compensation), while factitious disorder involves assuming the sick role without external reward. Options B and D are incorrect because BOTH conditions involve intentional, voluntary symptom production—these are shared features, not distinguishing ones. Option C is wrong because both conditions involve insight (unlike conversion disorder). Option E applies to both and doesn't distinguish them. The item is logically valid with one defensible best answer matching the key. Medical accuracy is sound: the distinction between external incentive (malingering) versus sick-role assumption (factitious disorder) aligns with DSM-5 criteria. Minimal fix: None needed; item is clear and accurate.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a patient in a personal injury lawsuit with inconsistent symptom presentation despite normal findings—classic malingering context. Key discriminating clues: (1) personal injury lawsuit context, (2) inconsistent presentations, (3) normal objective findings. The question asks what BEST DISTINGUISHES malingering from factitious disorder. Option A (secondary gain) is correct: malingering involves external incentives (lawsuit compensation), while factitious disorder involves assuming the sick role without external reward. Options B and D are incorrect because BOTH conditions involve intentional, voluntary symptom production—these are shared features, not distinguishing ones. Option C is wrong because both conditions involve insight (unlike conversion disorder). Option E applies to both and doesn't distinguish them. The item is logically valid with one defensible best answer matching the key. Medical accuracy is sound: the distinction between external incentive (malingering) versus sick-role assumption (factitious disorder) aligns with DSM-5 criteria. Minimal fix: None needed; item is clear and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]